- Funding will support commercialization of next-gen drug-coated balloons and expansion of intelligent manufacturing
- Investors are backing the company as it targets growth in coronary and peripheral vascular interventions
Barty Medical (巴泰医疗科技) has raised nearly 200 million yuan ($30 million) in a Series D financing round, as the Hangzhou-based vascular intervention device maker scales production and advances a new generation of drug-coated balloon technologies.
Shenzhen CDF Capital led the round, with participation from Zhejiang’s “4 plus 1” Biopharmaceutical and High-End Medical Device Industry Fund, Efung Capital, Nanjing Zhongyiren Investment and individual industry investors.
Existing shareholder Junxingjian Venture Capital also increased its investment.
Drug-coated balloon products
Barty said it will use the proceeds to commercialize its third-generation constrained drug-coated balloon products, generate additional clinical evidence, build a next-generation intelligent manufacturing base and fund research into future vascular intervention devices.
Founded in 2015 and headquartered in Hangzhou BioPharma Town, the company develops medical devices for vascular interventions.
It has built a product portfolio spanning vascular access, vessel preparation and implant-free drug therapies.
Regulators in China have approved 19 of its medical devices, and the company exports products to more than 40 countries and regions.
Vascular intervention
One of its flagship products, the Matrix Super PTX peripheral constrained drug-coated balloon, entered the market in July 2024.
Barty says it was China’s first and the world’s second third-generation vascular intervention balloon, combining controlled expansion with anti-restenosis treatment.
The company is also developing Matrix Crush, a constrained coronary drug-coated balloon designed for de novo lesions in large coronary vessels.
The product has completed patient enrollment in clinical trials and aims to address limitations of conventional drug-coated balloons, including limited dilation time and a higher risk of vessel dissection.
Commercialization
“Barty Medical focuses on the golden corridor of coronary and peripheral vascular interventions. Its core products have all been included in national volume-based procurement, opening market access nationwide,” the lead backer CDF Capital said.
The investor added that Barty’s constrained-balloon technology platform reduces endothelial damage associated with conventional balloon devices.
As newer products enter commercialization and existing products benefit from volume-based procurement programs, the company is poised for a new phase of growth, CDF Capital said.
